scispace - formally typeset
Journal ArticleDOI

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

TLDR
In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.
Abstract
Background Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. Methods We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. Results A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 ...

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Transoral laser microsurgery for recurrent laryngeal and pharyngeal cancer.

TL;DR: Transoral laser microsurgery offers select patients an attractive alternative salvage surgical therapy to the recurrent and second primary tumor site to reduce the likelihood of future treatment-related deaths.
Journal ArticleDOI

Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma

TL;DR: Conventional radiotherapy with concurrent cisplatin is significantly superior to induction cisPlatin fluorouracil chemotherapy followed by radiotherapy in terms of laryngeal preservation in patients with T3 hypopharyngeAL carcinoma.
Journal ArticleDOI

Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice.

TL;DR: To facilitate triaging of medical information, available publications on chemoradiotherapy of locally advanced squamous cell carcinoma of the head and neck were reviewed and practice-oriented recommendations for systemic treatment concurrent to definitive and post-operative radiotherapy were prepared.
Journal ArticleDOI

Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy

TL;DR: Elevated levels of TGF-β in the tumor microenvironment enable tumor cells to evade ADCC and resist the antitumor activity of cetuximab in vivo, and provide a rationale for combinatorial targeting of T GF-β to improve anti-EGFR–specific antibody therapy of EGFR-expressing cancers.
References
More filters
Book ChapterDOI

Nonparametric Estimation from Incomplete Observations

TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

TL;DR: In this article, a multiple comparison procedure for comparing several treatments with a control is presented, which is based on the Multiple Comparison Procedure for Comparing Several Treatments with a Control (MCPC).
Journal ArticleDOI

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

Robert Gray
- 01 Jan 1988 - 
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI

Cancer statistics, 2003.

TL;DR: The American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year, and compiles the most recent data on cancer incidence, mortality, and survival by using incidence data from the National Cancer Institute (NCI) and mortality data from National Center for Health Statistics (NCHS).
Related Papers (5)